Form 4: Stoke Therapeutics GC Sells Shares Under 10b5-1 Plan

Stoke Therapeutics General Counsel Jonathan Allan sold 9,293 shares of common stock on March 20, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported the sale of common stock.
• The transactions occurred on March 20, 2026.
• A total of 8,692 shares were sold at a weighted average price of $33.6354 per share, with prices ranging from $33.33 to $34.28.
• An additional 601 shares were sold at a weighted average price of $34.4079 per share, with prices ranging from $34.34 to $35.12.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Allan on November 10, 2025.
• Following these transactions, Mr. Allan beneficially owns 19,543 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale of shares by an insider under a pre-arranged 10b5-1 plan is a routine financial management activity and typically does not signal a change in company fundamentals or outlook.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 trading plans are a common practice for corporate executives. These plans allow insiders to pre-arrange sales of company stock to manage personal finances and diversify holdings, while providing an affirmative defense against claims of trading on material non-public information. Such routine sales are generally not indicative of management's view on the company's future prospects.

Stakeholder Impact

• Shareholders: Minimal direct impact, as routine insider sales under 10b5-1 plans are generally anticipated and do not typically reflect a change in company prospects.

Key Dates

Recommendation

The filing reports a routine insider sale executed under a pre-arranged 10b5-1 trading plan, which is a common practice for executives to manage personal finances and diversify holdings. This type of transaction does not typically indicate a change in the company's fundamentals or future prospects, thus a 'hold' recommendation is maintained.

Keywords

Stoke Therapeutics, STOK, Insider Trading, Form 4, Stock Sale, Jonathan Allan, 10b5-1 Plan